Skip to main content

Voluntary Scheme for Branded Medicines Pricing and Access

Question for Department of Health and Social Care

UIN 153959, tabled on 14 April 2022

To ask the Secretary of State for Health and Social Care, with reference to the Government's 2019 Voluntary Scheme for Branded Medicines Pricing and Access, what progress the Government is making on attaining its objective of reaching the upper quartile of uptake for the five highest health gain categories; who is accountable for the work on that objective; and if he will make a statement.

Answered on

25 April 2022

The five highest health gain (5HHG) categories are included in NHS Digital’s innovation scorecard estimates report. This shows that the use of the 5HHG categories was within the expected usage of the National Institute for Health and Care Excellence’s recommended medicines, with the exception of varenicline, which was lower than expected.

The Voluntary Scheme for Branded Medicines Pricing and Access is an agreement between the Department, on behalf of the Government, NHS England, the Association of the British Pharmaceutical Industry and manufacturers or suppliers of branded health service medicines which have joined the Scheme. All parties committed to the objective of reaching the upper quartile of uptake for the 5HHG categories in relation to comparator countries during the first half of the Voluntary Scheme.